BioAge Labs, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.
Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now. TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by […]
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Alex Bond initiated coverage on Coinshares PLC (NASDAQ:CSHR) with an Outperform rating and announces Price Target of $9. CoinShares shares closed at $6.11 on Tuesday. See how other analysts view this stock. BTIG analyst Thomas Shrader initiated coverage on BIOAGE L
Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes. See opinions on CSHR, BIOA.
AMD, Under Armour downgraded: Wall Street's top analyst calls
BioAge Labs, Inc. ( NASDAQ:BIOA ) investors will be delighted, with the company turning in some strong numbers with its...
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inflation, which soared to 3.8% annually, the highest since May 2023, while the core number, which is less food and energy, rose to ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap
BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $40.
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM EDTCompany...
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical results, plans for ne
Presenter SpeechChris Patil Welcome to the BioAge Labs R&D Day. I'm Chris Patil, VP Media at BioAge. Before we begin, I would like to remind everyone that during this call, we will be making...
BioAge Labs, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 22.25 million compared to USD 12.93 million a year...
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 44.44 percent decrease over losses of $(0.36) per share from the
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging...
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular...
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor April 21, 2026 8:00 AM EDTCompany ParticipantsChris...
BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory biomarkers—particularly high-sensitivity C-reactive protein (hs-CRP)—alongside a tolerability profile ma
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 850.9K | $14.88M | 0.00% | Added+101.2% | 2026-03-31 |
| DEShaw | quant | 699.2K | $12.23M | 0.01% | Added+105.7% | 2026-03-31 |
| FidelityFMR | fundamental | 190.3K | $3.33M | 0.00% | Added+61.7% | 2026-03-31 |
| RenTech | quant | 138.6K | $2.42M | 0.00% | Added+653.2% | 2026-03-31 |
| Wellington | fundamental | 67.7K | $1.18M | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 47.0K | $821.17K | 0.00% | Added+11.4% | 2026-03-31 |
| TRowePrice | fundamental | 21.4K | $375 | 0.00% | Added+44.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.64 | — | — |
| 2026-05-08 | -0.63 | -0.52 | +17.13% |
| 2026-03-24 | -0.67 | -0.72 | -7.69% |
| 2025-11-06 | -0.51 | -0.56 | -9.02% |
| 2025-08-06 | -0.38 | -0.60 | -57.31% |
| 2025-05-06 | -0.53 | -0.36 | +31.76% |
| 2025-03-20 | -0.66 | -1.75 | -167.75% |
| 2024-11-07 | -0.73 | -6.70 | -812.48% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BIOA | +2.98% | -15.49% | +30.69% | +336.62% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.01% | -10.86% | +34.13% | +323.93% |